Fever-Tree
Ticker: FEVR LN
Sector: Spirits
Rating: Buy
Published Research
Fever-Tree: H1 2025 Results (Quick Note) (September 2025)
Fever-Tree: ~20% Rebound on EBITDA Expectations … and Margot Robbie? (March 2025)
Fever-Tree: Solving U.S. Strategic Problem, Likely at the Right Price (February 2025)
Fever-Tree: H1 Showed Costs are On Track, Even if Growth is Not (Yet) (September 2024)
Fever-Tree: Long-Term Compounder; Takeover Potential Not Priced In (Initiation) (June 2024)